No Data
No Data
OAP III (HK) Limited, the majority shareholder of Baili Tianheng (688506.SH), reduced its holdings by 1.38% through an inquiry and transfer
Baili Tianheng (688506.SH) issued an announcement. In this inquiry and transfer, the company's shareholder OAP III (...
Baili Tianheng (688506.SH): Preliminary confirmation of the transfer price of this inquiry is 109.25 yuan/share
Baili Tianheng (688506.SH) issued an announcement. According to the inquiry and subscription situation on March 22, 2024, preliminary...
Shareholder of Baili Tianheng (688506.SH) OAP III (HK) Limited plans to transfer 1.50% of the shares through an inquiry
Baili Tianheng (688506.SH) issued an announcement. The company's shareholder OAP III (HK) Lim...
A-share changes | Bailitian Hengpan initially approaches 20CM rise and stop the new drug to obtain approval notice for phase I clinical trials
Glonghui, March 14 | Bailey Tianheng (688506.SH) was close to a 20CM rise and stop at the beginning of the session. It is now reported at 135.4 yuan, with a total market value of 54.3 billion yuan. The company announced yesterday after the market that the injectable BL-M05D1 (ADC) program for treating locally advanced solid tumors has obtained a Phase I clinical trial approval notice. In addition, a down payment of 800 million US dollars from BMS was recently received, and the FIC variety is expected to fulfill its global value.
Express News | Baili Tianheng: BL-M05D1 (ADC) for injectable treatment of locally advanced solid tumors obtained approval notice for phase I clinical trials
Bailey Tianheng-U (688506) Important Review: FIC varieties that have received a down payment of 800 million US dollars from BMS are expected to deliver on global value
Matters: On March 10, 2024, the company announced that it had received a down payment of US$800 million from BMS for the BL-B01D1 development and commercialization license agreement, which is expected to have a positive impact on the 2024 results.
No Data